Novartis may weigh Lucentis price cut in U.K.

A one-two punch from new studies has Novartis ($NVS) weighing a price cut on its eye drug Lucentis. Last week, data comparing that product to its close cousin, Avastin, in macular degeneration patient…
Read the full story: News